Cargando…

Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients

BACKGROUND: We investigated whether and to what extent the ratio between circulating fibrinogen (Fg) and its degradation products (FDP) reflects the severity of coronary artery disease (CAD) in type 2 diabetic patients. METHODS: Plasma levels of Fg and FDP were determined, and Fg/FDP ratio was calcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Wei-Xin, Shen, Ying, Dai, Dao-Peng, Lu, Lin, Zhang, Qi, Zhang, Rui-Yan, Shen, Wei-Feng, Tao, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833973/
https://www.ncbi.nlm.nih.gov/pubmed/25758263
http://dx.doi.org/10.4103/0366-6999.152465
_version_ 1782427421722542080
author Xiong, Wei-Xin
Shen, Ying
Dai, Dao-Peng
Lu, Lin
Zhang, Qi
Zhang, Rui-Yan
Shen, Wei-Feng
Tao, Rong
author_facet Xiong, Wei-Xin
Shen, Ying
Dai, Dao-Peng
Lu, Lin
Zhang, Qi
Zhang, Rui-Yan
Shen, Wei-Feng
Tao, Rong
author_sort Xiong, Wei-Xin
collection PubMed
description BACKGROUND: We investigated whether and to what extent the ratio between circulating fibrinogen (Fg) and its degradation products (FDP) reflects the severity of coronary artery disease (CAD) in type 2 diabetic patients. METHODS: Plasma levels of Fg and FDP were determined, and Fg/FDP ratio was calculated in 344 consecutive patients with type 2 diabetes and chest pain on exertion undergoing coronary angiography. The severity of CAD was evaluated by the number of significant CAD (>50% luminal diameter narrowing) and Gensini score. RESULTS: Plasma Fg was higher, but Fg/FDP ratio was lower in patients with significant CAD (n = 255) compared with those without (n = 89), due to a disproportionate increase in FDP. Fg and FDP correlated positively, while Fg/FDP ratio negatively, with the number of diseased coronary arteries and the tertile of Gensini score (all P values for trend < 0.01). After adjusting for age, sex, risk factors for CAD, lipid profiles, glycosylated hemoglobin A1c, creatinine, leukocyte count, and high-sensitivity C-reactive protein, Fg/FDP ratio remained an independent determinant for multivessel coronary disease (MVD) (odds ratio [OR], 0.869; 95% confidence interval [CI], 0.788–0.958, P = 0.005) and high tertile of Gensini score (OR, 0.797, 95% CI, 0.682–0.930, P = 0.004). The area under the curve of Fg/FDP ratio was larger than that of Fg for predicting the presence of MVD (0.647 vs. 0.563, P = 0.048) and Gensini score ≥ 30 (0.656 vs. 0.538, P = 0.026). CONCLUSIONS: Elevated plasma Fg and FDP level and reduced Fg/FDP ratio are associated with presence of CAD, and Fg/FDP ratio is superior to Fg in reflecting severe coronary atherosclerosis for patients with type 2 diabetes.
format Online
Article
Text
id pubmed-4833973
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48339732016-04-29 Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients Xiong, Wei-Xin Shen, Ying Dai, Dao-Peng Lu, Lin Zhang, Qi Zhang, Rui-Yan Shen, Wei-Feng Tao, Rong Chin Med J (Engl) Original Article BACKGROUND: We investigated whether and to what extent the ratio between circulating fibrinogen (Fg) and its degradation products (FDP) reflects the severity of coronary artery disease (CAD) in type 2 diabetic patients. METHODS: Plasma levels of Fg and FDP were determined, and Fg/FDP ratio was calculated in 344 consecutive patients with type 2 diabetes and chest pain on exertion undergoing coronary angiography. The severity of CAD was evaluated by the number of significant CAD (>50% luminal diameter narrowing) and Gensini score. RESULTS: Plasma Fg was higher, but Fg/FDP ratio was lower in patients with significant CAD (n = 255) compared with those without (n = 89), due to a disproportionate increase in FDP. Fg and FDP correlated positively, while Fg/FDP ratio negatively, with the number of diseased coronary arteries and the tertile of Gensini score (all P values for trend < 0.01). After adjusting for age, sex, risk factors for CAD, lipid profiles, glycosylated hemoglobin A1c, creatinine, leukocyte count, and high-sensitivity C-reactive protein, Fg/FDP ratio remained an independent determinant for multivessel coronary disease (MVD) (odds ratio [OR], 0.869; 95% confidence interval [CI], 0.788–0.958, P = 0.005) and high tertile of Gensini score (OR, 0.797, 95% CI, 0.682–0.930, P = 0.004). The area under the curve of Fg/FDP ratio was larger than that of Fg for predicting the presence of MVD (0.647 vs. 0.563, P = 0.048) and Gensini score ≥ 30 (0.656 vs. 0.538, P = 0.026). CONCLUSIONS: Elevated plasma Fg and FDP level and reduced Fg/FDP ratio are associated with presence of CAD, and Fg/FDP ratio is superior to Fg in reflecting severe coronary atherosclerosis for patients with type 2 diabetes. Medknow Publications & Media Pvt Ltd 2015-03-20 /pmc/articles/PMC4833973/ /pubmed/25758263 http://dx.doi.org/10.4103/0366-6999.152465 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Xiong, Wei-Xin
Shen, Ying
Dai, Dao-Peng
Lu, Lin
Zhang, Qi
Zhang, Rui-Yan
Shen, Wei-Feng
Tao, Rong
Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title_full Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title_fullStr Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title_full_unstemmed Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title_short Clinical Utility of the Ratio Between Circulating Fibrinogen and Fibrin (ogen) Degradation Products for Evaluating Coronary Artery Disease in Type 2 Diabetic Patients
title_sort clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833973/
https://www.ncbi.nlm.nih.gov/pubmed/25758263
http://dx.doi.org/10.4103/0366-6999.152465
work_keys_str_mv AT xiongweixin clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT shenying clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT daidaopeng clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT lulin clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT zhangqi clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT zhangruiyan clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT shenweifeng clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients
AT taorong clinicalutilityoftheratiobetweencirculatingfibrinogenandfibrinogendegradationproductsforevaluatingcoronaryarterydiseaseintype2diabeticpatients